BE
BEAM.US Beam Therapeutics Inc
- Market cap
- USD 2.43B
- P/E
- -
- P/B
- 2.61x
- ROE
- -49.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BEAM.US undervalued?
Graham numberThe Graham number of Beam Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beam Therapeutics Inc fundamental analysis
No fundamental analysis for Beam Therapeutics Inc yet.
Beam Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin d…
Full company profileBeam Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beam Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 18.0K | 24.0K | 51.8M | 60.9M | 378M | 63.5M | 140M | 43.4M |
| Gross Profit | -11.0K | -33.9M | -54.6M | -103M | -180M | -251M | 378M | -304M | 117M | 43.4M |
| Operating Income | -8.60M | -45.7M | -75.2M | -133M | -392M | -338M | -176M | -416M | -384M | -500M |
| EBITDA | -8.59M | -45.1M | -71.7M | -128M | -230M | -272M | -111M | -355M | -14.0M | -447M |
| Net Income | -8.73M | -115M | -78.3M | -195M | -371M | -289M | -133M | -377M | -80.0M | -469M |
| EPS | -0.67 | -3.28 | -1.53 | -4.16 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 | -4.48 |
| Balance Sheet | ||||||||||
| Total Assets | 2.40M | 167M | 156M | 452M | 1.47B | 1.34B | 1.46B | 1.10B | 1.48B | 1.27B |
| Total Liabilities | 6.59M | 33.0M | 55.2M | 206M | 648M | 608M | 478M | 370M | 243M | 316M |
| Shareholders' Equity | -4.18M | 134M | 101M | 246M | 827M | 733M | 981M | 734M | 1.24B | 953M |
| Cash & Short-term Investments | 1.90M | 146M | 91.8M | 300M | 966M | 1.08B | 1.19B | 851M | 1.25B | 1.04B |
| Total Debt | 1.01M | - | 31.2M | 108M | 148M | 179M | 173M | 161M | 294M | 244M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.71M | -20.3M | -72.0M | -95.7M | -66.3M | 22.5M | -149M | -347M | -345M | -407M |
| Capital Expenditure | 346K | 13.1M | 12.5M | 16.4M | 46.8M | 49.0M | 33.7M | 8.95M | 14.9M | 7.81M |
| Free Cash Flow | -3.05M | -33.4M | -84.5M | -112M | -113M | -26.4M | -183M | -356M | -360M | -415M |
| Ratios | ||||||||||
| ROE | - | -86.0% | -77.6% | -79.2% | -44.8% | -39.4% | -13.5% | -51.4% | -6.5% | -49.2% |
| ROA | -363.4% | -69.0% | -50.2% | -43.1% | -25.1% | -21.5% | -9.1% | -34.1% | -5.4% | -36.9% |
| Net Profit Margin | - | - | -435,144.4% | -810,800.0% | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% | -1,080.1% |
| Debt to Equity | - | - | 0.31x | 0.44x | 0.18x | 0.24x | 0.18x | 0.22x | 0.24x | 0.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beam Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 12.7M | 0.25 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Beam Therapeutics Inc
- Insiders 1.20%
- Institutions 98.80%
- Public & others 0.00%
- Shares outstanding 103M
- Free float 88.1M
Top funds holding BEAM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Innovation ETF | 6.17M | 5.96% | -3.15% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.69M | 3.57% | +2.68% | Oct 2026 |
| Fidelity Growth Company Fund | 3.46M | 3.34% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.29M | 3.18% | +0.38% | Sep 2026 |
| ARK Genomic Revolution ETF | 3.06M | 2.95% | +0.73% | Oct 2026 |
| iShares Russell 2000 ETF | 2.52M | 2.44% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 2.33M | 2.25% | -1.67% | Sep 2026 |
| Amova ARK Disruptive Innovation A USD | 2.30M | 2.22% | +2.58% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.29M | 1.25% | -4.98% | Sep 2026 |
| Fidelity Small Cap Index | 1.09M | 1.05% | +0.14% | Aug 2026 |
| Fidelity Growth Company K6 | 984K | 0.95% | 0.00% | Aug 2026 |
| Amova ARK Pstv Chg Innovt P JPY Acc | 868K | 0.84% | +10.17% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 834K | 0.81% | -0.38% | Oct 2026 |
| Fidelity Series Growth Company | 781K | 0.75% | -3.31% | Aug 2026 |
| iShares Biotechnology ETF | 732K | 0.71% | -0.19% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 709K | 0.69% | -13.39% | Sep 2026 |
| Fidelity Select Pharmaceuticals Port | 595K | 0.58% | +18.94% | Sep 2026 |
| Vanguard Russell 2000 ETF | 576K | 0.56% | +0.99% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 532K | 0.51% | +0.24% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 494K | 0.48% | 0.00% | Sep 2026 |
Top institutions holding BEAM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 12.6M | 12.18% | +1.26% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 10.2M | 9.89% | +1.00% | Jun 2026 |
| ARK Investment Management LLC | 10.2M | 9.89% | -15.65% | Jun 2026 |
| BlackRock Inc | 9.00M | 8.69% | +6.01% | Jun 2026 |
| State Street Corp | 5.83M | 5.63% | +2.24% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.92M | 4.76% | +7.67% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.60M | 4.44% | +5.07% | Jun 2026 |
| ARCH VENTURE CORP | 4.54M | 4.39% | 0.00% | Jun 2026 |
| Amova Asset Management Americas, Inc | 3.46M | 3.34% | -9.69% | Jun 2026 |
| Sumitomo Mitsui Trust Group Inc | 3.46M | 3.34% | -9.69% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.42M | 3.30% | +25.87% | Jun 2026 |
| Kynam Capital Management, LP | 2.84M | 2.74% | -22.85% | Jun 2026 |
| Geode Capital Management, LLC | 2.60M | 2.51% | +7.38% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.17M | 2.09% | -2.68% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 1.95M | 1.89% | +200.95% | Jun 2026 |
| Contrarius Group Holdings Ltd | 1.61M | 1.56% | +202.66% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 1.55M | 1.50% | -6.16% | Jun 2026 |
| Two Sigma Investments LLC | 1.39M | 1.34% | +14.65% | Jun 2026 |
| Casdin Capital, LLC | 1.35M | 1.30% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.31M | 1.27% | +30.26% | Jun 2026 |
Beam Therapeutics Inc company profile
- Company name
- Beam Therapeutics Inc
- Ticker
- BEAM.US
- Exchange
- USA Stocks
- Listed since
- Feb 6, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 557
- Fiscal year end
- December
- Address
- 238 Main Street, Cambridge, MA, United States, 02142
- Phone
- 857 327 8775
- Website
- beamtx.com
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Beam Therapeutics Inc management
10- Mr. John M. Evans M.B.A.CEO & Director · born 1978
- Dr. Giuseppe Ciaramella Ph.D.President · born 1969
- Mr. Sravan Kumar EmanyChief Financial Officer · born 1978
- Dr. Christine P. Bellon J.D., Ph.D.Chief Legal Officer & Corporate Secretary · born 1966
- Dr. Amy Simon M.D.Chief Medical Officer · born 1965
- Dr. Feng Zhang Ph.D.Co-Founder
- Dr. David R. Liu Ph.D.Co-Founder
- Dr. J. Keith Joung M.D., Ph.D.Co-Founder
- Ms. Bethany J. Cavanagh M.B.A.Senior VP of Finance, Treasurer & Principal Accounting Officer
- Dr. Manmohan Singh Ph.D.Chief Technology Officer